Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

Leukemia and Lymphoma

Volumn 54, Issue 4, 2013, Pages 683-687

  Zhu, Yuan Xiao ^a   Kortuem, K Martin ^a   Stewart, A Keith ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cereblon; IMiDs; Myeloma

Indexed keywords

CEREBRAL PROTEIN; ENDOPEPTIDASE LA; INTERFERON REGULATORY FACTOR 4; LENALIDOMIDE; POMALIDOMIDE; PROTEIN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER CELL CULTURE; CELL SURVIVAL; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TERATOGENICITY; TREATMENT RESPONSE;

GENE EXPRESSION; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON REGULATORY FACTORS; MULTIPLE MYELOMA; PEPTIDE HYDROLASES; TERATOGENS; THALIDOMIDE;

EID: 84876724199     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.728597     Document Type: Review

References (56)

1. Speirs AL. Th alidomide and congenital abnormalities. Lancet 1962; 1: 303-305.
2. Sheskin J. Th alidomide in the treatment of lepra reactions. C lin Pharmacol Ther 1965; 6: 303-306.
3. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
4. Juliusson G, Celsing F, Turesson I, et al. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000; 109: 89-96.
5. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289-3294.
6. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reducedintensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 2007; 370: 1209-1218.
7. Palumbo A, Bringhen S, Liberati A M, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized controlled trial. Blood 2008; 112: 3107-3114.
8. Muller GW, Corral LG, Shire MG, et al. Structural modifi cations of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem 1996; 39: 3238-3240.
9. Marriott J B, Muller G, Stirling D, et al. Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin Biol Ther 2001; 1: 675-682.
10. Madan S, Lacy MQ, Dispenzieri A, et al. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood; 118: 1763-1765.
11. Wang M, Dimopoulos MA, Chen C, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008; 112: 4445-4451.
12. Guglielmelli T, Bringhen S, Rrodhe S, et al. Previous thalidomide therapy may not aff ect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. Eur J Cancer 2011; 47: 814-818.
13. Lacy MQ, Teff eri A. Pomalidomide therapy for multiple myeloma and myelofi brosis. Leuk Lymphoma 2011; 52: 560-566.
14. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009; 2: 36.
15. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010; 24: 22-32.
16. Escoubet-Lozach L, Lin I L, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009; 69: 7347-7356.
17. Keifer JA, Guttridge DC, Ashburner BP, et al. Inhibition of NFkappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001; 276: 22382-22387.
18. Li S, Pal R, Monaghan SA, et al. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E downregulation resulting in inhibition of MM. Blood 2011; 117:5157-5165.
19. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 2002; 99: 4525-4530.
20. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996; 87: 1104-1112.
21. Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95: 2630-2636.
22. Gupta D, Treon S P, Shima Y, et al. A dherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia 2001; 15: 1950-1961.
23. Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic applications. Oncogene 2001; 20: 4519-4527.
24. Geitz H, Handt S, Zwingenberger K. Th alidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996; 31: 213-221.
25. Hideshima T, Bergsagel PL, Kuehl WM, et al. Advances in biology of multiple myeloma: Clinical applications. Blood 2004; 104: 607-618.
26. Breitkreutz I, Raab MS, Vallet S, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008; 22: 1925-1932.
27. Anderson G, Gries M, Kurihara N, et al. Th alidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006; 107: 3098-3105.
28. Kumar S, Witzig TE, Dispenzieri A, et al. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia 2004; 18: 624-627.
29. Haslett PA, Corral LG, Albert M, et al. Th alidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8 + subset. J Exp Med 1998; 187: 1885-1892.
30. Davies FE, Raje N, Hideshima T, et al. Th alidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-216.
31. Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009; 58: 1033-1045.
32. Braga WM, Atanackovic D, Colleoni GW. The role of regulatory T cells and TH17 cells in multiple myeloma. Clin Dev Immunol 2012; 2012: 293479.
33. Giannopoulos K, Kaminska W, Hus I, et al. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: Detailed characterisation of immune status in multiple myeloma. Br J Cancer 2012; 106: 546-552.
34. Zhu D, Corral LG, Fleming YW, et al. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008; 57: 1849-1859.
35. Wu L, Adams M, Carter T, et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20 + tumor cells. Clin Cancer Res 2008; 14: 4650-4657.
36. Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012 May 3. [Epub ahead of print]
37. Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 1999; 5: 582-585.
38. Knobloch J, Shaughnessy JD Jr, Ruther U. Th alidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. FASEB J 2007; 21: 1410-1421.
39. Hansen JM, Gong SG, Philbert M, et al. Misregulation of gene expression in the redox-sensitive NF-kappab-dependent limb outgrowth pathway by thalidomide. Dev Dyn 2002; 225: 186-194.
40. Hansen JM, Harris C. A novel hypothesis for thalidomide-induced limb teratogenesis: Redox misregulation of the NF-kappaB pathway. Antioxid Redox Signal 2004; 6: 1-14.
41. D' Amato RJ, Loughnan MS, Flynn E, et al. Th alidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085.
42. Th erapontos C, Erskine L, Gardner E R, et al. Th alidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci USA 2009; 106: 8573-8578.
43. Ito T, Ando H, Suzuki T, et al. Identifi cation of a primary target of thalidomide teratogenicity. Science 2010; 327: 1345-1350.
44. Higgins J J, Pucilowska J, Lombardi R Q, et al. A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology 2004; 63: 1927-1931.
45. Angers S, Li T, Yi X, et al. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 2006; 443: 590-593.
46. Zhu Y X, Braggio E, Shi C X, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118: 4771-4779.
47. Bjorklund C C, M a W, Wang Z Q, et al. Evidence of a role for activation of Wnt/{beta}-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 2011; 286: 11009-11020.
48. Heintel D, Bolomsky A, Schreder M, et al. High expression of the thalidomide-binding protein cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Blood 2011; 118(Suppl. 1): Abstract 2879.
49. Neri P, Belch AR, Johnson J, et al. A miRNA risk score for the prediction of response to lenalidomide in multiple myeloma (MM) patients. Blood 2011; 118(Suppl. 1): Abstract 987.
50. Shaff er AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature 2008; 454: 226-231.
51. Lopez-Girona A, Heintel D, Zhang LH, et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 2011; 154: 325-336.
52. Yang Y, Shaff er A L 3rd, Emre N C, et al. Exploiting synthetic lethality for the therapy of ABC Diffuse large B cell lymphoma. Cancer Cell 2012; 21: 723-737.
53. Higgins JJ, Hao J, Kosofsky BE, et al. Dysregulation of largeconductance Ca2 + -activated K + channel expression in nonsyndromal mental retardation due to a cereblon p.R419X mutation. Neurogenetics 2008; 9: 219-223.
54. Jo S, Lee KH, Song S, et al. Identifi cation and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain. J Neurochem 2005; 94: 1212-1224.
55. Lee K M, J o S, Kim H, et al. Functional modulation of AMP-activated protein kinase by cereblon. Biochim Biophys Acta 2011; 1813: 448-455.
56. Baumann P, Mandl-Weber S, Emmerich B, et al. Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells. Exp Cell Res 2007; 313: 3592-3603.